CLINICAL RESEARCH: INTERVENTIONAL CARDIOLOGY
Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous coronary intervention
John P. A. Ioannidis, MD* ,*,
Evangelia Karvouni, MD and
Demosthenes G. Katritsis, MD, PhD, FACC
* Clinical Trials and Evidence-Based Medicine Unit, Department of Hygiene and Epidemiology, University of Ioannina School of Medicine and the Biomedical Research Institute, Foundation for Research and Technology, Hellas– Ioannina, Greece
Division of Clinical Care Research, Tufts-New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts, USA
Department of Cardiology, Athens Euroclinic, Athens, Greece
Manuscript received February 26, 2003;
revised manuscript received April 4, 2003,
accepted April 10, 2003.
* Reprint requests and correspondence: Dr. John P. A. Ioannidis, Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina 45110, Greece.
jioannid{at}cc.uoi.gr
OBJECTIVES: The aim of this study was to assess whether small creatine kinase-MB isoenzyme (CK-MB) elevations after percutaneous coronary intervention (PCI) affect the subsequent mortality risk.
BACKGROUND: Several studies have evaluated the relationship of CK-MB levels after PCI with the subsequent risk of death. While there is consensus that elevations exceeding 5 times the upper limit of normal increase mortality significantly, there is uncertainty about the exact clinical impact of smaller CK-MB elevations.
METHODS: We performed a meta-analysis of seven studies with CK-MB measurements and survival outcomes on 23,230 subjects who underwent PCI. Data were combined with random effects models.
RESULTS: Mean follow-up was 6 to 34 months per study. By random effects, 19% (95% confidence interval [CI], 16% to 23%) had one- to five-fold CK-MB elevations, while only 6% (95% CI, 5% to 9%) had >5-fold elevations. Compared with subjects with normal CK-MB, there was a dose-response relationship with relative risks for death being 1.5 (95% CI, 1.2 to 1.8, no between-study heterogeneity) with one- to three-fold CK-MB elevations, 1.8 (95% CI, 1.4 to 2.4, no between-study heterogeneity) with three- to five-fold CK-MB elevations, and 3.1 (95% CI, 2.3 to 4.2, borderline between-study heterogeneity) with over five-fold CK-MB elevations (p < 0.001 for all).
CONCLUSIONS: Any increase in CK-MB after PCI is associated with a small, but statistically and clinically significant, increase in the subsequent risk of death.
|
Abbreviations and Acronyms
| | CI | = confidence interval | | CK-MB | = creatine kinase-MB isoenzyme | | EPIC | = Evaluation of IIb/IIIa Platelet Receptor Antagonist 7E3 in Preventing Ischemic Complications trial | | EPILOG | = Evaluation in PTCA to Improve Long-term Outcome with Abciximab Glycoprotein IIb/IIIa Blockade trial | | IMPACT-II | = Integrilin (eptifibatide) to Minimize Platelet Aggregation and Coronary Thrombosis-II study | | PCI | = percutaneous coronary intervention | | PTCA | = percutaneous transluminal coronary angioplasty |
|
This article has been cited by other articles:
|
|
|
|
 
S. Tsimikas
High-Dose Statins Prior to Percutaneous Coronary Intervention: A Paradigm Shift to Influence Clinical Outcomes in the Cardiac Catheterization Laboratory
J. Am. Coll. Cardiol.,
December 1, 2009;
54(23):
2164 - 2166.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. B. Lindsey, S. P. Marso, M. Pencina, J. M. Stolker, K. F. Kennedy, C. Rihal, G. Barsness, R. N. Piana, S. L. Goldberg, D. E. Cutlip, et al.
Prognostic Impact of Periprocedural Bleeding and Myocardial Infarction After Percutaneous Coronary Intervention in Unselected Patients: Results From the EVENT (Evaluation of Drug-Eluting Stents and Ischemic Events) Registry
J. Am. Coll. Cardiol. Intv.,
November 1, 2009;
2(11):
1074 - 1082.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Hara, M. Nakamura, I. Yokouchi, K. Kimura, N. Nemoto, S. Ito, T. Ono, H. Itaya, M. Shiba, M. Wada, et al.
Aggressive statin therapy in multicenter and effectiveness for the reduction of intra-myocardial damage caused by non-ST elevation acute coronary syndrome: AMERICA study
Therapeutic Advances in Cardiovascular Disease,
October 1, 2009;
3(5):
357 - 365.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. S.P. Sharp, A. Latib, A. Ielasi, C. Larosa, C. Godino, M. Saolini, V. Magni, R. T. Gerber, M. Montorfano, M. Carlino, et al.
Long-Term Follow-Up on a Large Cohort of "Full-Metal Jacket" Percutaneous Coronary Intervention Procedures
Circ Cardiovasc Interv,
October 1, 2009;
2(5):
416 - 422.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Sanchis, V. Bodi, J. Nunez, L. Mainar, E. Nunez, P. Merlos, E. Rumiz, G. Minana, X. Bosch, and A. Llacer
Efficacy of Coronary Revascularization in Patients With Acute Chest Pain Managed in a Chest Pain Unit
Mayo Clin. Proc.,
April 1, 2009;
84(4):
323 - 329.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. G. Katritsis and B. Meier
Percutaneous Coronary Intervention for Stable Coronary Artery Disease
J. Am. Coll. Cardiol.,
September 9, 2008;
52(11):
889 - 893.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Y. Wang, E. D. Peterson, D. Dai, H. V. Anderson, S. V. Rao, R. G. Brindis, M. T. Roe, and on behalf of the National Cardiovascular Data Regi
Patterns of Cardiac Marker Surveillance After Elective Percutaneous Coronary Intervention and Implications for the Use of Periprocedural Myocardial Infarction as a Quality Metric: A Report From the National Cardiovascular Data Registry (NCDR)
J. Am. Coll. Cardiol.,
May 27, 2008;
51(21):
2068 - 2074.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Nusca, R. Melfi, and G. Di Sciascio
Review: Percutaneous coronary interventions and statins therapy
Therapeutic Advances in Cardiovascular Disease,
April 1, 2008;
2(2):
101 - 107.
[Abstract]
[PDF]
|
|
|
|
|
|
|
K. Thygesen, J. S. Alpert, H. D. White, and on behalf of the Joint ESC/ACCF/AHA/WHF Task Force
Universal Definition of Myocardial Infarction
J. Am. Coll. Cardiol.,
November 27, 2007;
50(22):
2173 - 2195.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Thygesen, J. S. Alpert, H. D. White, on behalf of the Joint ESC/ACCF/AHA/WHF Task Force, TASK FORCE MEMBERS: Chairpersons: Kristian Thygese, Biomarker Group: Allan S. Jaffe, Coordinator (USA), ECG Group: Bernard Chaitman, Co-ordinator (USA), P, Imaging Group: Richard Underwood, Coordinator (UK), Intervention Group: Jean-Pierre Bassand, Co-ordina, Clinical Investigation Group: Paul W. Armstrong, C, et al.
Universal Definition of Myocardial Infarction
Circulation,
November 27, 2007;
116(22):
2634 - 2653.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Task Force Members, K. Thygesen, J. S. Alpert, H. D. White, Biomarker Group, A. S. Jaffe, F. S. Apple, M. Galvani, H. A. Katus, L. K. Newby, et al.
Universal definition of myocardial infarction: Kristian Thygesen, Joseph S. Alpert and Harvey D. White on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction
Eur. Heart J.,
October 2, 2007;
28(20):
2525 - 2538.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Schiano and P. Gabriel Steg
Measurement and prevention of myocardial injury during percutaneous coronary intervention
Heart,
June 1, 2007;
93(6):
656 - 657.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.-H. Lee, A. Low, B.-C. Tai, M. Co, M. Y. Chan, J. Lim, Y.-T. Lim, and H.-C. Tan
Pretreatment with intracoronary adenosine reduces the incidence of myonecrosis after non-urgent percutaneous coronary intervention: a prospective randomized study
Eur. Heart J.,
January 1, 2007;
28(1):
19 - 25.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Balian, M. Galli, C. Marcassa, G. Cecchin, M. Child, F. Barlocco, E. Petrucci, G. Filippini, R. Michi, and M. Onofri
Intracoronary ST-Segment Shift Soon After Elective Percutaneous Coronary Intervention Accurately Predicts Periprocedural Myocardial Injury
Circulation,
October 31, 2006;
114(18):
1948 - 1954.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. J. Gomes and E. Buffolo
Coronary stenting and inflammation: implications for further surgical and medical treatment.
Ann. Thorac. Surg.,
May 1, 2006;
81(5):
1918 - 1925.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Herrmann
Peri-procedural myocardial injury: 2005 update
Eur. Heart J.,
December 1, 2005;
26(23):
2493 - 2519.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. L. Bhatt and E. J. Topol
Periprocedural Cardiac Enzyme Elevation Predicts Adverse Outcomes
Circulation,
August 9, 2005;
112(6):
906 - 922.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. E. Cutlip and R. E. Kuntz
Cardiac Enzyme Elevation After Successful Percutaneous Coronary Intervention Is Not an Independent Predictor of Adverse Outcomes
Circulation,
August 9, 2005;
112(6):
916 - 923.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Cavallini, S. Savonitto, R. Violini, G. Arraiz, M. Plebani, Z. Olivari, P. Rubartelli, S. Battaglia, L. Niccoli, G. Steffenino, et al.
Impact of the elevation of biochemical markers of myocardial damage on long-term mortality after percutaneous coronary intervention: results of the CK-MB and PCI study
Eur. Heart J.,
August 1, 2005;
26(15):
1494 - 1498.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. P.A. Ioannidis, E. Karvouni, and D. G. Katritsis
Creatine Kinase-MB Elevation Following Stent Implantation
J. Am. Coll. Cardiol.,
June 7, 2005;
45(11):
1908 - 1908.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Jeremias, D. S. Baim, R. E. Kuntz, and D. E. Cutlip
Reply
J. Am. Coll. Cardiol.,
June 7, 2005;
45(11):
1908 - 1909.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. G. Katritsis and J. P.A. Ioannidis
Percutaneous Coronary Intervention Versus Conservative Therapy in Nonacute Coronary Artery Disease: A Meta-Analysis
Circulation,
June 7, 2005;
111(22):
2906 - 2912.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I Porto, D J Blackman, D Nicolson, G Niccoli, F Z Kahn, O Ormerod, C Forfar, K Channon, and A P Banning
What is the incidence of myocardial necrosis in elective patients discharged on the same day following percutaneous coronary intervention?
Heart,
December 1, 2004;
90(12):
1489 - 1490.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Jeremias, D. S. Baim, K. K.L. Ho, M. Chauhan, J. P. Carrozza Jr, D. J. Cohen, J. J. Popma, R. E. Kuntz, and D. E. Cutlip
Differential mortality risk of postprocedural creatine kinase-MB elevation following successful versus unsuccessful stent procedures
J. Am. Coll. Cardiol.,
September 15, 2004;
44(6):
1210 - 1214.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Pasceri, G. Patti, A. Nusca, C. Pristipino, G. Richichi, G. Di Sciascio, and on behalf of the ARMYDA Investigators
Randomized Trial of Atorvastatin for Reduction of Myocardial Damage During Coronary Intervention: Results From the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) Study
Circulation,
August 10, 2004;
110(6):
674 - 678.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. G Katritsis
Elevation of CK-MB following percutaneous coronary intervention
Eur. Heart J.,
July 1, 2004;
25(13):
1180 - 1180.
[Full Text]
[PDF]
|
|
|
|
